Purpose: The purpose of this study is to evaluate the short-term clinical and oncological outcome of prolonging operation interval to 11 weeks after the end of radiotherapy for locally advanced middle and low rectal cancer. Methods: A total of 123 patients with stage II/III (cT3/T4 or N+) low and middle rectal cancer who had undergone operation after neoadjuvant chemoradiotherapy were selected. According to the interval time between the last radiotherapy and operation, they were assigned to a short-interval group (SG, <11 weeks, n=66) and long-interval group (LG, ≥11 weeks, n=57). The relations among interval time and short-term clinical outcome and oncological outcome were analyzed. Results: The analysis found that basic information, clinical characteristics, and preoperative treatment between the two groups had no significant difference. There were no differences in operation time, estimated intraoperative blood loss and postoperative complications. The rate of sphincter preservation in the low and middle rectum was 66.7% in the short-interval group and 59.7% in the long-interval group (P=0.42). The incidence of anastomotic leak in the long-interval group was higher than that in the short-interval group (P=0.08). There was no significant difference in the recovery time of intestinal function and median duration of hospitalization between the two groups. The pathological complete remission rate was 17.07%. Multivariate analysis showed interval time had no influence on pathological complete remission. There was no significant difference in 3-year overall survival and 3-year disease-free survival between the two groups. The risk of recurrence and metastasis in patients with positive lymph nodes was higher than those with negative lymph nodes (P<0.05), HR=4.812 (95% CI 2.4-9.648). Conclusion: Prolonging the interval time of operation to 11 weeks after neoadjuvant chemoradiotherapy for middle and low rectal cancer does not improve the pathologic complete remission, morbidity, and mortality. There was no significant effect on oncologic outcome after prolonging the operation interval. Therefore, it is safe to prolong the interval of operation to 11 weeks.
Introduction
In recent years, the incidence of colorectal cancer (CRC) has increased year by year. CRC has become the second most common cause of cancer-related death. 1 Many patients in China suffer from locally advanced rectal cancer (LARC) when they are diagnosed. Total mesorectal excision (TME) operation after neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment regimen for LARC. Neoadjuvant chemoradiotherapy can effectively control local tumors, make tumors shrink, increase sphincter preservation rate, and reduce local recurrence of tumors. Compared with postoperative radiotherapy and chemotherapy, nCRT can improve the prognosis of patients. [2] [3] [4] [5] [6] However, the time interval between the end of radiotherapy and TME operation remains controversial.
In 1999, the Lyon R90-01 randomized trial divided patients with LARC into 2 weeks and 6-8 weeks after nCRT. The results showed that the 6-8 weeks group had better tumor regression, downstage, sphincter preservation rate, and pathological complete remission (pCR) rate than the 2-week group. 7 Since then, the interval of 6-8 weeks has been considered as the most appropriate time for operation after nCRT. The distant control, overall survival (OS), and disease-free survival (DFS) of patients with rectal cancer after nCRT have been improved, and some of them can achieve pCR. Pathological complete remission is closely correlated with local control, DFS, and OS. 8, 9, [18] [19] [20] [21] Studies have shown that prolonging the interval between the last radiotherapy and operation can achieve pathological complete remission rate, but does not increase complications. 10, 15, 16 Tumor regression is linked with time. The interval of operation recommended in NCCN guidelines for rectal cancer after long-term radiotherapy is also changing, from the original 4-6 weeks to 5-12 weeks currently. 11 In addition, the Chinese Criteria for Diagnosis and Treatment of Colorectal Cancer also recommends 5-12 weeks as a reasonable interval after neoadjuvant chemoradiotherapy for stage II and III rectal cancer, which is consistent with NCCN guidelines. 12 It is obvious that prolonging the operation interval properly can lead to tumor regression further, even achieving complete remission. Prolonging the interval time can also help to improve the R0 resection rate, and reduce the positive rate of circumferential resection margin (CRM). Patients who have a strong desire for sphincter preservation with clinic complete remission have the opportunity to be selected in a "watch & wait" program (W&W). Nevertheless, studies have shown that prolonging the time interval after nCRT did not improve tumor remission and pathological complete response rate, reduce the incidence of postoperative complications and another adverse short-term clinical outcome instead. 13, 14 So far, there is no definite conclusion about the time interval of operation after neoadjuvant chemoradiotherapy.
With extension of time interval, the tissue fibrosis in the radiotherapy area can become severe, which can affect surgery. Planar fibrosis, severe edema, and local inflammation enhance difficulties in TME operation and complications of operation and reduce the R0 resection rate. 17, 26, 27 In addition, the prolongation of the time interval may increase the risk of local progression and distant metastasis, which can lead to patients missing the optimal operation time.
A prospective study showed that prolonging the operation time to 11 weeks after nCRT did not increase pCR, but caused higher intraoperative and postoperative morbidity. The 11-week group had a worse quality of TME than the 7-week group. 13 Therefore, we conducted a singlecenter retrospective study to explore the effect of extending the interval time to 11 weeks on short-term clinical outcome and tumor outcome.
Method
Patients with rectal cancer who experienced neoadjuvant chemoradiotherapy and radical surgical resection from 2010 to 2016 were selected from the First Affiliated Hospital of Chongqing Medical University. Preoperative, postoperative and follow-up data were collected.
Patient Selection
Altogether 148 patients with locally advanced rectal cancer (cT 3 /T 4 or N + ) who had undergone neoadjuvant chemoradiotherapy were selected from 2000 rectal cancer patients in the First Affiliated Hospital of Chongqing Medical University. Among them, there were 10 patients with high rectal cancer, 6 patients without follow-up after operation, 1 patient with rectal squamous carcinoma, 3 patients with signet ring cell cancer, 2 patients without operation because they could not preserve anal sphincter, one with distant metastasis during neoadjuvant chemoradiotherapy and 2 patients without inadequate preoperative data. Finally, 25 patients were excluded, and 123 patients were included. All patients included were over 18 years old.
Evaluation Before Neoadjuvant Chemoradiotherapy
Routine tumor estimation and physical examination before nCRT were carried out. Rectal adenocarcinoma (including mucinous adenocarcinoma) was confirmed by colonoscopy and pathological examination before operation. A computed tomography (CT) scan of chest, abdomen, and pelvis excluded distant organ metastases, such as liver and lung metastases. High-resolution magnetic resonance imaging (MRI) of the pelvis was used to evaluate the local rectal tumors, which contained T and N stage of rectal tumors according to AJCC (American Joint Committee on Cancer Stage), long diameter, and the distance of anal verge, separation, circumferential resection margin (CRM), and extramural vascular invasion (EMVI).
Process on Neoadjuvant Chemoradiotherapy
The long-course radiotherapy with a dose of 45-50.4 Gy was divided into 25-28 times, 1.8-2.0 Gy each time, which was completed within five and a half weeks. Capecitabine at 825 mg/m 2 was given orally twice a day during radiotherapy. Some patients received standard capecitabine and oxaliplatin neoadjuvant chemotherapy (nCT) in the period of interval time. Each cycle consisted of intravenous oxaliplatin with 130 mg/m 2 on day 1, and oral administration capecitabine with 1000 mg/m 2 twice on day 1 to day 14.
Preoperative Assessment
All patients went through a digital rectal examination before surgery. The enhanced CTs of chest, abdomen, and pelvis were used to exclude distant organ metastasis. High-resolution magnetic resonance imaging (MRI) was used to re-evaluate local rectal tumors, including T stage, N stage, Mandard Tumor Regression Grading (TRG), CRM, and EMVI.
Outcome Assessment
The 
Follow-Up
Patients accepted follow-up every 3-6 months in the first 2 years after operation. In each follow-up, patients received a series of examinations, including digital rectal examination, blood count, blood chemistries, and digestive tract cancer spectrum (including CEA, CA19-9, and AFP).
Enhanced computed tomography (CT) of chest, abdomen, and pelvis was performed every 6 months. Colonoscopy was performed every 1-2 years after operation. Three-year disease-free survival and overall survival were also collected. Disease-free survival is defined as the time between the date of operation and the date of recurrence or metastasis. Overall survival was defined as the time between the date of operation and the date of death or final follow-up.
Statistical Analysis
Nonparametric data are represented by a median of interquartile range. Chi-square test or Fishers were used to test classification variables and rank-sum test continuous variables accurately and compare baseline and clinical characteristics. Univariate analysis was performed to evaluate that whether changing surgical treatment time (less than or greater than 11 weeks) affects short-term postoperative clinical outcome. The short-term clinical outcome included hospitalization time, anal exsufflation time, anal defecation time, eating liquid diet time, drainage tube extraction time, 30 days readmission, 30 days reoperation, 30 days mortality rate, anastomotic leakage, and other postoperative complications. Logistic analysis was used to analyze the factors affecting pathological complete remission. These factors included CEA level before nCRT, location of tumor before nCRT, T stage before nCRT, neoadjuvant chemotherapy, positive lymph nodes before nCRT, MRI EMVI (+) and interval time after radiotherapy. The data in the logistic regression analysis were expressed by dominance ratio, 95% confidence interval, and P-value. Kaplan-Meier estimation and Cox proportional regression analysis were used to analyze the three-year disease-free survival (DFS) and overall survival (OS) and draw the survivorship curve and disease-free survival curve. All statistics were completed by SPSS 21.0 software, and P<0.05 was statistical significance.
Results

Basic Information and Clinical Characteristics of Patients Before Neoadjuvant Chemoradiotherapy
One hundred and twenty-three patients with locally advanced rectal cancer underwent total mesorectal excision (TME) after neoadjuvant chemoradiotherapy. Table 3 . Logistic regression analysis showed that pathological complete remission was not correlated with CEA level before nCRT, location of tumors before nCRT, T stage before nCRT, neoadjuvant chemoradiotherapy, positive lymph nodes before nCRT, MRI EMVI (+) and operation interval after radiotherapy (Table 4 ).
Oncological Outcome
Among 123 patients with neoadjuvant chemoradiotherapy, 1 patient in the SG group died within 8 weeks after operation due to other reasons, and 122 patients were included in the tumor outcome analysis at length. There were 94 (77.05%) patients with adjuvant chemotherapy after the operation, among which there were 50 patients in SG and (Figure 2A) . The 3-year overall survival of the two groups was very similar, at 83.1% and 80.7%, respectively (P=0.824), with no statistical significance ( Figure 2B ). COX analysis showed that recurrence or metastasis after neoadjuvant chemoradiotherapy was correlated with positive lymph nodes (P<0.05), HR=4.812 (95% CI 2.4-9.648), overall survival time was correlated with positive lymph nodes (P=0.003), HR=4.348 (95% CI 1.67-11.349) ( Table 5 ).
Discussion
Currently, the time interval between the last radiotherapy and standard TME operation for rectal cancer after neoadjuvant chemoradiotherapy remains controversial. Most studies believed that the prolongation of operation interval could reduce the local recurrence rate, but precise interval time is still uncertain. 8, 9, [18] [19] [20] [21] This study prolonged the interval to 11 weeks and analyzed the surgical conditions, postoperative complications, pathological examination results, and oncological outcome.
The Lyon R90-01 randomized-controlled trial divided patients into 2-week and 6-8-week intervals for operation. The results showed that compared with the 2-week group, the 6-8-week group had better tumor regression, downstage, sphincter preservation rate, and pathological complete remission rate. Since then, 6-8 weeks had been considered as the best appropriate time for operation after nCRT. 7 Prolonging interval time could increase tumor regression, enabling patients to acquire enough neoadjuvant chemotherapy time, which might increase the possibility of pathological complete remission. 8, 9, [18] [19] [20] [21] Nevertheless, with the prolongation of the interval time, the tissue fibrosis in the radiotherapy area became more serious. Planar fibrosis, severe edema, and local inflammation increased the difficulty of TME operation and the related risks during operation. 17 Garcia-Aguilar et al 23 found that pelvis fibrosis was more severe with an 11-week interval time than with a 6-week interval time after nCRT. The randomized-controlled study of GRECCAR-6 13 showed that compared with a 7-week interval time, an 11-week interval time after nCRT would increase postoperative complications and the risk of local recurrence, and affect the quality of total mesorectal excision. However, the prolongation of interval time did not mean an increase in surgical difficulties and complications. Our study found that the estimated blood loss during the operation was basically identical when the interval time was prolonged to 11 weeks. Although the pelvis fibrosis gradually increased after 11 weeks, the edema gradually subsided in the radiotherapy area, and the anatomical plane of the surgical area was clear. Therefore, prolonging to 11 weeks did not increase the operation time, intraoperative bleeding, and complications. After nCRT, the rate of sphincter preservation in middle and low rectal cancer would increase. 7 Huntington et al 24 found that the rate of sphincter preservation was not correlated with interval time, but sphincter preservation rate would decrease if the interval time was extended to 60 days. The sphincter preservation rate of middle and low rectal cancer in our study was 66.7% (SG) and 59.6% (LG), respectively. It might be inferred that the tumors would not shrink after reaching a certain time point, which is the best time for surgery. Moore et al 10 observed that anastomotic leakage and pelvis abscesses happened more frequently when the operation was carried out after an interval time of 44 days. The present study revealed that the incidence of anastomotic leakage in LG was higher than SG. It illustrated that complications after nCRT for rectal cancer had nothing to do with prolongation of interval Number of positive lymph nodes 0(0-1) 0(0-1.5) 0.302c
Abbreviations: m, Mann--Whitney; c, chi-square; TRG, tumor regression grading; pCR, pathological complete remission; SG, short-interval group;
LG, longinterval group; T, tumor; N, nodal; TN, tumor and nodal stage; ypT, pathological tumor stage after neoadjuvant therapy; ypN, pathological nodal stage after neoadjuvant therapy; ypTN, pathological tumor and nodal stage after neoadjuvant therapy; cT, clinic tumor stage; cN, clinic nodal stage; cTN, clinic tumor and nodal stage; ypT 0 N 0 , pathological tumor 0 stage and nodal 0 stage after neoadjuvant therapy. time 25 . Prolonging interval time could relieve intestinal edema, which was beneficial to getting a clean anatomic planner and better anastomosis. Nevertheless, most patients with sphincter preservation accepted preventive stoma in order to avoid serious postoperative complications, which caused the number of anastomotic leakages observed in the study to be lower than the actual number. Previous studies have found that DNA destruction of tumor cells mediates apoptosis leading to tumor regression, which is closely related to the interval time. Prolonging the interval time properly could provide better tumor regression and higher pathological complete remission rate. 22, [28] [29] [30] [31] It has been reported that about 30% of rectal tumors did not shrink and 6% of rectal tumorsgained progression after appropriate nCRT. 31 The degree of tumor regression is closely correlated with the prognosis of oncology. 32, 34, 35 Pathological complete remission indicates a good prognosis. 8, 9, [18] [19] [20] [21] Sloothaaket et al 33 found that the highest PCR rate (18.0%) could be obtained by prolonging the operation interval to 10-11 weeks after nCRT. It has been proven that as the interval time increased within 12 weeks, the rate of tumor regression and pCR rate increased gradually, which would decrease over 12 weeks interval time. 14 and prolonging interval time over 8 weeks would clearly increase the pathological complete remission rate. However, some other studies have shown that prolonging the interval time after nCRT did not increase pCR; instead, this would increase postoperative complications and the occurrence of distant metastasis during the waiting period. 13, 14 Our study showed that the pathological complete remission rate was 16.7% (11/66) in SG and 17.5% (10/57) in LG. Multivariate analysis showed that pCR of tumors had nothing to do with interval time; meanwhile, prolonging interval time did not increase the pCR. A meta-analysis showed that there was no significant difference in 5-year overall survival and disease-free survival between the group with an interval time within 6-8 weeks and over 6-8 weeks. 36 Similar conclusions were drawn in our study that 3-year overall survival and diseasefree survival in SG were superior to LG. Appropriate prolongation of interval time could make tumors regress further and provide opportunities for R 0 resection, which could reduce local recurrence and distant metastasis as far as possible. However, another study found that the 5-year OS and DFS of patients with interval time over 8-weeks were lower, compared with an interval time of less than 8 weeks. 37 Prolonging interval time increases pelvis fibrosis, which made it difficult to distinguish the operation plane, increased the difficulty of operation, reduced the quality of TME, decreased chances to complete R 0 resection, and increased the risk of local recurrence and distant metastasis; as a result, overall survival and disease-free survival for patients would decline. Erkan et al 38 carried out a study which showed that the 5-year overall survival of patients after nCRT with lymph node-negative was better than with lymph node-positive (80 vs 86%, P=0.014 HR=1.74, 95% CI 1.33-2.28). It indicated that positive lymph node was a risk factor for oncologic outcome. Studies have reported that lymph node metastasis occurred in 6-17% of patients with primary tumor complete remission (ypT 0 ) after neoadjuvant chemoradiotherapy. 39, 40 Twenty-two patients had complete regression (ypT 0 ) after nCRT in our study, including one patient with positive lymph node in the longinterval group and the rate of positive lymph node was 4.5%. There were two possible reasons for the phenomenon above. In the first place, the radiotherapy dose in the lymphatic drainage area was lower than for the primary tumor. Secondly, the tumor metastasized to lymph nodes because of an interval time that was too long. Survival analysis showed that a positive lymph node was an important influencing factor for 3-year overall survival. The 3-year disease-free survival was also closely correlated with positive lymph nodes. A tumor with positive lymph node was defined as TNM stage III, which had a lower survival rate and higher risks of local recurrence and distant metastasis than tumors with negative lymph node. Therefore, rectal cancer after nCRT with pathological complete regression (ypT 0 N 0 ) had a better oncologic outcome.
There are many limitations to this study. Firstly, the study is a single-center retrospective study, which may have selection bias. Although a large amount of basic information is collected, there is information bias still. Secondly, recurrence and metastasis of rectal cancer occurred mostly in the first three years after operation. The follow-up time of most patients was 3 years, which was insufficient to evaluate the prognosis of rectal cancer, including survival rate. Thirdly, postoperative complications were not classified according to Clavien-Dindo complications, which caused imprecise analysis. Finally, the regimen and times of preoperative and postoperative chemotherapy may affect the pathological results and oncological outcome. We did not compare the regimen and times of chemotherapy between the two groups in the study.
Conclusion
In conclusion, prolonging the interval time to 11 weeks after neoadjuvant chemoradiotherapy for middle and low rectal cancer does not increase the pathologic complete remission, morbidity, and mortality. There is no significant effect on oncologic outcome after prolonging the interval time to 11 weeks. Therefore, it is safe to prolong interval time to 11 weeks. It is necessary to carry out a larger prospective randomized study so that the precise interval time after nCRT can be confirmed, which will conduct better oncological outcome.
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